Abstract
Molecular pathology presents a particularly difficult challenge to the systematic methodology proposed by evidence-based pathology for the gathering of evidence and classification of such evidence using various evidence level schemes. The rapid developments in the field, complexity of molecular tests, massive quantity of data accrued, and the almost infinite number of analytes addressed by these new technologies render many of the requirements delineated in this chapter – for positive mutation controls, clinical validation, etc. – almost moot. Clearly the genie is out of the bottle, and we have little choice but to move forward thoughtfully, incorporating the approaches we have described when possible, but not adhering to them so rigidly that patients are deprived for too long of their access to these potentially life-saving technologies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. Health Aff (Millwood). 2008;27(6):1600–11.
Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, editors. Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Oxford: Oxford University Press; 2004. p. 217–33.
Eagle A. Seal of approval ACCE rolls out a new certification for clinical engineers. Health Facil Manage. 2004;17(5):30–2, 34.
Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. Genet Med. 2002;4(2):90–4.
Palomaki GE, Bradley LA, Richards CS, Haddow JE. Analytic validity of cystic fibrosis testing: a preliminary estimate. Genet Med. 2003;5(1):15–20.
Palomaki GE, Haddow JE, Bradley LA, Richards CS, Stenzel TT, Grody WW. Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing. Genet Med. 2003;5(6):440–3.
Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing. Genet Med. 2007;9(7):473–8.
McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008;10(2):89–98.
Maddalena A, Bale S, Das S, Grody W, Richards S. Technical standards and guidelines: molecular genetic testing for ultra-rare disorders. Genet Med. 2005;7(8):571–83.
Briss PA, Brownson RC, Fielding JE, Zaza S. Developing and using the guide to community preventive services: lessons learned about evidence-based public health. Annu Rev Public Health. 2004;25:281–302.
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med. 2009;11(1):3–14.
Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008;59:429–42.
Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009;11(6):543–52.
Rossi E, Jeffrey GP. Clinical penetrance of C282Y homozygous HFE haemochromatosis. Clin Biochem Rev. 2004;25(3):183–90.
Bushby KM. Genetic and clinical correlations of Xp21 muscular dystrophy. J Inherit Metab Dis. 1992;15(4):551–64.
Little J, Bradley L, Bray MS, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156(4):300–10.
Richards CS, Grody WW. Prenatal screening for cystic fibrosis: past, present and future. Expert Rev Mol Diagn. 2004;4(1):49–62.
Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination as a consequence of genetic testing. Am J Hum Genet. 1992;50(3):476–82.
Erwin C. Legal update: living with the Genetic Information Nondiscrimination Act. Genet Med. 2008;10(12):869–73.
Schlich-Bakker KJ, Ausems MG, Schipper M, Ten Kroode HF, Warlam-Rodenhuis CC, van den Bout J. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2008;109(3):507–14.
Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14(12):1060–74.
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749–64.
ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn. 2008;10(6):484–92.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wei, JP.J., Grody, W.W. (2011). Evidence-Based Pathology and Laboratory Medicine in the Molecular Pathology Era: Transition of Tests from the Research Bench into Practice. In: Marchevsky, A., Wick, M. (eds) Evidence Based Pathology and Laboratory Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1030-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1030-1_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1029-5
Online ISBN: 978-1-4419-1030-1
eBook Packages: MedicineMedicine (R0)